Jen Ge, Ph.D. focuses her practice on intellectual property in the biotechnology and pharmaceutical fields. Her practice includes drafting and prosecuting patent applications on, but is not limited to, antibody therapeutics, cancer immunotherapies, gene therapies, cell-based therapies, drug delivery, and diagnostic assays. She also conducts IP due diligence in mergers, acquisitions, IPOs, and other transactions, and performs patentability assessments and freedom-to-operate analyses. Jen also provides technical support for patent litigations in the biopharma space, and assists in infringement and validity opinions. Prior to joining Morgan Lewis, Jen was a patent agent at another major general practice law firm.
Previously, Jen interned at Yale University Technology Transfer Office, where she examined issues of commercialization and patentability related to inventions produced by the university faculties. During her postdoctoral research at Yale Stem Cell Center, she studied mechanisms of maintaining genome stability during stem cell self-renewal and differentiation. Jen’s doctoral thesis focused on DNA damage and genome integrity during eukaryotic DNA replication. She also worked at Eli Lilly & Company on drug target validation for central nervous system-related diseases.
Jen has authored numerous peer-reviewed articles in journals including Genes & Development, Journal of Cell Biology, EMBO Report, and Genome Biology.
University of Dundee, Scotland, 2008, Ph.D., Cell and Molecular Biology
University of Liverpool, 2004, B.Sc., Honors Biochemistry
US Patent and Trademark Office
Awards and Affiliations
Member, Practice Group of the Year, Intellectual Property, Law360 (2019)
Member, Litigation Department of the Year–Intellectual Property, The American Lawyer (2019)